Back to discover
Drug

Urea

In clinical development
Emerging researchLate-stage development
Also known as Accuzyme, AllanEnzyme, AllanfillEnzyme, Aluvea+66 more

Accuzyme, AllanEnzyme, AllanfillEnzyme, Aluvea, Amino-Cerv, Aqua Care, Aquaphilic with Urea, Atrac-Tain, CEM-Urea, Carbamide, Carbamide Peroxide Otic, Carbonyldiamide, Carmol, Cerovel, Dermasorb XM, Dermatol 10, Ear Drops, Epimide 50, Ero Ear Wax, Ethezyme, Gladase, Gladase-C, Gormel, Gormel 10, Harnstoff, Hydrasyn25, Hydro 35, Hydro 40, Karbamid, Kera Nail, Kera-42, Kerafoam, Keralac, Keratol, Keratol 40, Kerol, Kovia, Lanaphilic with Urea, Latrix, Mectalyte, Nutraplus, Panafil White, Pap-Urea, Papain-Urea, Papfyll, Paptase, Proxigel, Rea Lo 39, Rea-Lo, Remeven, U-Kera, U-Lactin, Ultra Mide, Ultralytic, Ultralytic 2, Umecta, Umecta PD, Uramaxin, Uramaxin GT, Uramaxin GT Kit, Ureacin-10, Ureacin-20, Urealac, Ureaphil, Utopic, Vanamide, X-Viate, Ziox, Panafil, Chlorophyllin Copper Complex/Papain/Urea.

2
Research papers
1
Active clinical trials

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Urea
Aliases & brands
AccuzymeAllanEnzymeAllanfillEnzymeAluveaAmino-CervAqua CareAquaphilic with UreaAtrac-TainCEM-UreaCarbamideCarbamide Peroxide OticCarbonyldiamideCarmolCerovelDermasorb XMDermatol 10Ear DropsEpimide 50Ero Ear WaxEthezymeGladaseGladase-CGormelGormel 10HarnstoffHydrasyn25Hydro 35Hydro 40KarbamidKera NailKera-42KerafoamKeralacKeratolKeratol 40KerolKoviaLanaphilic with UreaLatrixMectalyteNutraplusPanafil WhitePap-UreaPapain-UreaPapfyllPaptaseProxigelRea Lo 39Rea-LoRemevenU-KeraU-LactinUltra MideUltralyticUltralytic 2UmectaUmecta PDUramaxinUramaxin GTUramaxin GT KitUreacin-10Ureacin-20UrealacUreaphilUtopicVanamideX-ViateZioxPanafilChlorophyllin Copper Complex/Papain/Urea
RxNorm CUI
11002
ChEMBL ID
CHEMBL985
ATC codes
D02AE01B05BC02D02AE51
UNII
8W8T17847W

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2017
1
Active studies
5
Late-stage (III+)
3
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 6
Phase 21Phase 32Phase 41Phase N / A2

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Positron Emission Tomography Computed Tomography1Prostate-Specific Antigen1
Journals, researchers & institutions
Top journals
  • The Journal of urology1
  • The New England journal of medicine1
Leading researchers
  • Abbasi SA1
  • Adams KF1
  • Alva AS1
  • Anand I1
  • Arias-Mendoza A1
  • Biering-Sørensen T1
  • Böhm M1
  • Bonderman D1
Leading institutions
free-text, unnormalised
  • Brigham and Women's Hospital/Dana-Farber Cancer Institute1
  • CHU de Quebec and Laval University1
  • Jewish General Hospital1
  • Johns Hopkins University School of Medicine1
  • Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center1
  • Memorial Sloan Kettering Cancer Center1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 2 of the same disease areas as Urea in the shared literature.

2 shared diseases1 shared paper

Studied across 2 of the same disease areas as Urea in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials